Levitra free base

Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5.

For research use only. Not for human or veterinary use.

Target Phosphodiesterase (PDE)

Research area Endocrinology Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

Levitra structure

CAS No.: 224785-90-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 g	USD 750.00	BP-01996-100g	In stock	Get quote
500 g	Inquire	BP-01996-500g	In stock	Inquire

Custom Size Bulk Inquiry

Description

Biological activity

Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels.

Identifiers

SMILES: CCCC1=NC(C)=C2N1N=C(NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1
InChIKey: SECKRCOLJRRGGV-UHFFFAOYSA-N

Specifications

MW (average): 488.6030
Formula: C₂₃H₃₂N₆O₄S
CAS No.: 224785-90-4
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Saenz de Tejada I, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001;13(5):282-290.

[2]. Ashour AE, et al. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-544.

[3]. Gresser U, et al. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res. 2002 Oct 29. 7(10):435-46.

[4]. Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov. 60(5):1020-

Same target

Search Phosphodiesterase (PDE)

Same research area

Search Endocrinology